Pathological changes of a malignant liver tumor after systemic therapies

Systemic therapeutic regimens for malignant tumors are usually determined on the basis of the pathologic diagnosis. Patients usually undergo later-line regimens for the same tumor pathology without re-biopsy when they experience progressive disease (PD). In this report, we describe a patient with a malignant liver tumor in which the pathology transformed from intrahepatic cholangiocarcinoma (ICC) to hepatocellular carcinoma (HCC) after a partial response and PD following systemic therapies for ICC. The patient maintained stable disease with a regimen for HCC after PD following the ICC regimen. This case showed the possible transformation of tumor pathologic features with systemic therapies. The results suggest the potential necessity to reconfirm the pathologic features of malignant liver tumors when patients experience PD after a response to systemic therapies.

Authors

Institutions

Publication Details

Journal
Hepatology Research
Published
2025-04-04
DOI
https://doi.org/10.1111/hepr.14184
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pathological changes of a malignant liver tumor after systemic therapies

Hidenori Toyoda, Shirou Kuwabara, Satoshi Yasuda, Yuichi Koshiyama et al.
Hepatology Research
Hepatocellular Carcinoma Treatment and Prognosis
article

Pathological changes of a malignant liver tumor after systemic therapies

Hidenori Toyoda, Shirou Kuwabara, Satoshi Yasuda, Yuichi Koshiyama, Yukihiro Shiraki, Y Kinoshita
article en

Abstract

Systemic therapeutic regimens for malignant tumors are usually determined on the basis of the pathologic diagnosis. Patients usually undergo later-line regimens for the same tumor pathology without re-biopsy when they experience progressive disease (PD). In this report, we describe a patient with a malignant liver tumor in which the pathology transformed from intrahepatic cholangiocarcinoma (ICC) to hepatocellular carcinoma (HCC) after a partial response and PD following systemic therapies for ICC. The patient maintained stable disease with a regimen for HCC after PD following the ICC regimen. This case showed the possible transformation of tumor pathologic features with systemic therapies. The results suggest the potential necessity to reconfirm the pathologic features of malignant liver tumors when patients experience PD after a response to systemic therapies.

Hepatology ResearchVol. 55(6)
Ogaki Municipal Hospital (JP), Nagoya University (JP)
Openalex Percentile: Top 91%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Pathological changes of a malignant liver tumor after systemic therapies — Hidenori Toyoda, Shirou Kuwabara, et al. · Hepatology Research (2025) | TGRS Research Map | TGRS